Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
University of California, Davis
40 participants
Oct 17, 2024
INTERVENTIONAL
Conditions
Summary
The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.
Eligibility
Inclusion Criteria6
- Acute subarachnoid hemorrhage
- Age greater than 18 years
- Secured aneurysm
- Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision
- maker
- Patient or surrogate decision maker is available to consent
Exclusion Criteria8
- Less than 18 years old
- Unsecured aneurysm
- Pregnant or lactating
- Prisoner
- Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker
- Nasal or facial trauma or surgery within the last three months
- Allergy to lidocaine, bupivacaine, or dexamethasone
- Patient is unable to consent and no available surrogate decision maker
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06621329